Method of treating attention deficit disorders with d-threo methylphenidate

• US 20060030587A1
• Filed: 10/06/2005
• Published: 02/09/2006
• Est. Priority Date: 12/04/1995
• Status: Abandoned Application

• Current Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Original Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Inventors: Zeitlin, Andrew L., Dariani, Maghsoud M., Stirling, David L.
• Application Number:
  US11/244,924
• Publication Number:
  US 20060030587A1
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate
• CPC Class Codes: A61K 9/1676 having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921
• CPC Class Codes: A61K 9/2886 having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/209
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 211/34 with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C12P 17/12 containing a six-membered hetero ring
• CPC Class Codes: C12P 41/006 by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Abstract

Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.

Claims

1. A method of treating Attention Deficit Disorder on a daily basis while reducing side effects associated with the administration of racemic threo methylphenidate which comprises administrating on a daily basis to a human in need thereof an amount of D-threo methylphenidate or a pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, wherein the amount administered is effective to treat Attention Deficit Disorder while reducing side effects associated with racemic threo methylphenidate.

2. The method according to claim 1 wherein the amount administered is 5 mg to 50 mg per day.

3. The method according to claim 2 wherein the amount administered is 5 mg per day.

4. The method according to claim 1 wherein the amount of said d-threo methylphenidate or a pharmaceutically equivalent salt thereof is greater than 90% of the total amount of methylphenidate.

5. The method according to claim 4 wherein the amount of said d-threo methylphenidate or a pharmaceutically equivalent salt thereof is greater than 99% of the total amount of methylphenidate.

6. The method according to claim 1 wherein the side effects are anorexia, weight loss, insomnia, dizziness, or dysphoria.

7. The method according to claim 1 wherein the side effect is a euphoric effect.

8. The method according to claim 1 wherein the side effect is drug abuse potential.

9. The method according to claim 1 wherein the amount of D-threo methylphenidate enhances therapeutic activity compared to racemic methylphenidate.

10. The method according to claim 1 wherein the administration is daily.

11. The method according to claim 1 wherein the administration is one to four times per day.

12. The method according to claim 1 wherein said amount of D-threo methylphenidate or pharmaceutically acceptable salt thereof comprises a carrier or diluent.